The inactivating TP53 and RB1 mutations were detected 1 or 2 years before clinical progression, which supported the notion that EGFR-TKI-resistant SCLC cells branches out at the early stage from the adenocarcinoma clones [28]. This evidence concerns the gene TP53 and adenocarcinoma.